Late pericarditis secondary to pericardial patch implantation 25 years prior

Abstract

We report a rare case of a 50-year-old man with signs of right heart failure due to localized pericarditis that was secondary to implantation of an artificial pericardial patch 25 years prior following pericardectomy for constrictive pericarditis. The patient's clinical symptoms resolved completely in the 3 years following patch removal.

Living patches engineered from human umbilical cord derived fibroblasts and endothelial progenitor cells☆

“…Such non-autologous materials have been associated with substantial complications including calcifications, obstructive tissue ingrowth, infections, and thrombogenicity [1,3,17]. The availability of living graft materials with the potential to grow, regenerate and to adapt to the changes in the developing cardiovascular system would have fundamental advantages over currently used replacement materials.…”

“…Myofibroblasts were isolated from umbilical cord tissue of newborns. Several (z8 mm 3 ) pieces of umbilical cord tissue were washed with PBS, placed in petri-dishes and cultured in a humidified incubator (37 8C, 5% CO 2 ) in advanced DMEM medium (Gibco, Invitrogen) supplemented with 10% fetal bovine serum (PAN Biotech, Germany), 2 mM Glutamax (Gibco) and Gentamycin (50 mg/ml, PAN). Myofibroblasts were expanded up to passage 11.…”

“…Currently, paediatric surgical treatment requires the application of synthetic or non-autologous bioprosthetic materials, such as patches and vascular conduits [1,2]. These materials are burdened with substantial disadvantages including obstructive tissue ingrowth and calcification of the replacement [3]. These limitations and the lack of growth typically cause re-operations of paediatric patients with cardiovascular defects associated with increased morbidity and mortality.…”

The Development of Tissue-Engineered Grafts for Reconstructive Cardiothoracic Surgical Applications

“…Shortcomings of these patches include the inability to grow, remodel, and regenerate as well as increased risk of infection and aneurysm. These constructs are also subject to obstructive tissue ingrowth and fibrotic responses with shrinkage and calcification leading to graft failure (67). Autologous pericardium is difficult to handle (68,69) while synthetic patches are associated with thromboembolic complications, hemolysis, and infective endocarditis (70,71).…”

Human umbilical cord cells: a new cell source for cardiovascular tissue engineering

“…Prosthetic replacements lack growth potential and can become obstructed by tissue ingrowth or calcification, leading to the need for multiple replacements [1,2]. All synthetic material is thrombogenic and, after implantation, the risk of thrombembolic and infectious complications potentially increases [3]. Cryopreserved homograft tissue appears to offer advantages over prosthetic re-placements by theoretically providing some viability with a potential ability for growth [4 -6].…”